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Abstract 
Review on Follicular Dendritic Cell Sarcoma, with 
data on clinics, and the genes involved. 
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Clinics and pathology 
Disease 
Follicular dendritic cell sarcoma (FDCS) is an 
extremely rare mesenchymal neoplasm. This tumor 
was first reported in 1986 by Monda et al. and is 
classified by the World Health Organization (WHO) 
under histiocytic and dendritic cell neoplasms. 
Phenotype/cell stem origin 
The cell of origin is the antigen presenting follicular 
dendritic cell. Normal (Non-neoplastic) follicular 
dendritic cells process antigen antibody complexes, 
and present them to B-cells in lymphoid follicles 
(Wu et al., 2016). 
Etiology 
The etiology is unknown. Rare cases have been 
described in association with the hyaline vascular 
type of Castleman disease (Youens et al., 2008). 
Epidemiology 
Follicular dendritic cell sarcomas are extremely rare. 
The number of reported cases are fewer than 100. 
Patients as young as 9 up to 82 years old have been 
described, though it occurs predominantly in adults. 
Mean and median age of disease are in the fifth 
decade of life. Both sexes are equally affected. 
Clinics 
Most cases of follicular dendritic cell sarcoma 
present with asymptomatic lymphadenopathy. 
Cervical and axillary lymph nodes are commonly 
affected. Extra nodal sites that can be involved 
include spleen, liver, gastrointestinal tract, skin, 
lung, mediastinum, pharynx, tonsils and soft tissue. 
Patients with intra-abdominal tumors may suffer 
from abdominal pain. Other systemic presentations 
include fever, night sweats and fatigue. Rarely 
paraneoplastic myasthenia gravis and pemphigus has 
been reported in FDCS (Wang et al., 2016). 
Abnormal levels of alkaline phosphatase as well as 
anemia are reported with hepatic involvement by 
FDCS. 
Pathology 
The tumor shows various histologic patterns of 
spindle cells in storiform (the most common form), 
meningioma -like (whorled), fascicles, bundles or 
diffuse sheets; heterogenicity in growth patterns can 
also be seen. Tumor cells are plump with indistinct 
cell borders (syncytial appearance) and show 
fibrillary slightly eosinophilic cytoplasm. Tumor 
cells have vesicular nuclei with fine chromatin, 
sometimes intranuclear pseudoinclusions, and 
nucleoli; binucleate cells are present. Perivascular B 
or T lymphocytes can be seen. In some cases TdT+ 
T-lymphoblasts can be associated with these tumors 
(Ohgami et al., 2012, 2013, 2014). 
Tumor necrosis is unusual and the mitotic rate can 
vary from 0 to 10 per 10 high power fields.  
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Figure 1:  Histopathologic features of a follicular dendritic cell sarcoma (FDCS). Numerous spindled shaped elongated cells are 
seen with finer nuclear chromatin and frequently prominent nucleoli, some binucleate (red arrows) cells are clearly seen which is 
typical of FDCS. 
High mitotic rates are more common in cases with 
cytologic atypia and clinically aggressive behavior. 
Treatment 
Complete surgical excision is the treatment of choice 
for both primary and recurrent cases. The benefits 
and advantages of radiotherapy and chemotherapy 
are not established yet. In cases with a BRAF V600 
mutation, a BRAF enzyme inhibitor such as 
vemurafenib can be a potential choice. Another 
therapeutic agent are EGFR inhibitors, especially in 
cases which express moderate to strong EGFR. 
Prognosis 
Extranodal tumors have a higher risk of metastases 
than nodal counterparts. Local recurrences are 
common. Liver, lung and lymph nodes are common 
metastatic sites. Tumors with larger size (>6cm) 
significant cellular atypia, coagulative necrosis, 
intra-abdominal location and high mitotic rate 
(greater than 5 mitoses in 10 hpf) have unfavorable 
prognosis. 
Cytogenetics 
Cytogenetics morphological 
No specific chromosomal aberration has been 
established in FDCS. Non-recurrent types of 
complex cytogenetic abnormalities have been 
documented (Udayakumar et al., 2015; Perry et al., 
2013). 
Cytogenetics molecular 
The genetic alterations that drive tumorogenesis are 
not well understood in FDCS. One recent study that 
assessed the genetic basis of FDCS reported BRAF 
V600 mutations in a subset of cases (Go et al., 2014). 
Another study analyzing somatic alterations, showed 
loss of function alterations in tumor suppressor 
genes (NF-kB regulatory genes), including bi-allelic 
loss of CYLD and frameshift mutations in NFKBIA. 
Alterations in genes that regulate cell cycle include 
bi-allelic loss of CDKN2A and RB-1. Finally, focal 
copy-number gains on chromosome 9p24, a well 
described mechanism of immune evasion, have been 
observed in the regions containing CD274 (PD-L1) 
and PDCD1LG2 (PD-L2) (Griffin et al., 2016). 
Genes involved and 
proteins 
BRAF (v-raf murine sarcoma viral 
oncogene homolog B1) 
Location 7q34 
Protein 
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This gene belongs to the RAF/MIL family of 
serine/threonine kinases. The protein product affects 
cell division, secretion and differentiation through its 
regulating role in the MAP kinase/ERK signaling 
pathway. Mutations have been associated with 
cancers including malignant melanoma, colorectal 
cancer, non-Hodgkin lymphoma, thyroid carcinoma, 
non-small cell lung carcinoma, and adenocarcinoma 
of lung. 
CYLD (cylindromatosis (turban tumor 
syndrome)) 
Location 16q12.1 
Protein 
The product of this gene is a cytoplasmic protein. 
The role of this gene in FDCS is purportedly through 
negative regulation of NF-kB activation by bi-allelic 
loss of CYLD gene. 
NFKBIA (NFKB inhibitor alpha) 
Location 14q13.2 
Protein 
NFKBIA is a member of the NF-kappa-B inhibitor 
family and involved in inflammatory responses. The 
alteration in FDCS is a frameshift mutation or 
deletion in NFKBI resulting in altered cytoplasmic 
sequestration of NF-kB complex. 
CDKN2A (cyclin dependent kinase 2a 
/ p16) 
Location 9p21.3 
Protein 
This gene generates several transcripts differing in 
their first exon. At least three spliced variants encode 
distinct proteins. The most well-known proteins are 
p16 (INK4a) and p14 (ARF) which both have tumor 
suppressor activity. 
RB1 (retinoblastoma) 
Location 13q14.2 
Protein 
This gene encodes a protein which is a negative 
regulator of the cell cycle. Bi-allelic losses of RB1 
are seen, as well as nonsense mutations in FDCS. 
CD274 (CD274 molecule) 
Location 9p24.1 
Protein 
The protein product of PD-L1 is involved in T-cell 
proliferation, activation and the production of 
cytokines like IL-10 and IFN-gamma. It is 
considered to be prognostic in various types of 
malignancies, including renal cell carcinoma and 
colon cancer. 
PDCD1LG2 (programmed cell death 1 
ligand 2) 
Location 9p24.1 
Protein 
PD-L2 is involved in T-cell proliferation and INF-
gamma production. In some cases of FDCS, a copy 
number gain on chromosome 9p24 in the location of 
these genes was observed, and believed to contribute 
to immune system evasion. 
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